美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

UTHR 美国联合医疗

休市中 06-18 16:00:00 EDT

536.59

-14.88

-2.70%

盘后536.59

+0.000.00%

19:05 EDT

最高555.23	最低532.59	成交量200.20万
今开553.18	昨收551.47	日振幅4.11%
总市值227.71亿	流通市值208.88亿	总股本4,244万
成交额10.76亿	换手率5.14%	流通股本3,893万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"UTHR","market":"US","secType":"STK","nameCN":"美国联合医疗","latestPrice":536.59,"timestamp":1781812800000,"preClose":551.47,"halted":0,"volume":2001977,"hourTrading":{"tag":"盘后","latestPrice":536.59,"preClose":536.59,"latestTime":"19:05 EDT","volume":721749,"amount":387283732.70468,"timestamp":1781823942892,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.026982428781257357,"floatShares":38926400,"shares":42437200,"eps":27.065825,"marketStatus":"休市中","change":-14.88,"latestTime":"06-18 16:00:00 EDT","open":553.18,"high":555.23,"low":532.59,"amount":1076127301.3571,"amplitude":0.041054,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":27.065825,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":929592000000,"exchange":"NASDAQ","adjPreClose":551.47,"preHourTrading":{"tag":"盘前","latestPrice":548,"preClose":551.47,"latestTime":"09:25 EDT","volume":1,"amount":548,"timestamp":1781789100081,"change":-3.47,"changeRate":-0.006292,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":536.59,"preClose":536.59,"latestTime":"19:05 EDT","volume":721749,"amount":387283732.70468,"timestamp":1781823942892,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.540252224918328,"impliedVol":0.3374,"impliedVolPercentile":0.1355},"requestUrl":"/m/hq/s/UTHR","defaultTab":"news","newsList":[{"id":"1185929543","title":"Varda Space Industries与联合医疗携手推进微重力罕见肺病疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185929543","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185929543?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:02","pubTimestamp":1778666549,"startTime":"0","endTime":"0","summary":"Varda Space Industries与联合医疗（United Therapeutics）达成合作，共同致力于利用微重力环境开发针对罕见肺部疾病的创新疗法。此次合作旨在探索太空环境对药物研发与生产可能带来的革命性影响，为相关治疗领域开辟新的技术路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","UTHR","LU1571399168.USD","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106467182","title":"美国联合医疗董事雷蒙德·德韦克教授荣休 曾获C.B.E.及F.R.S.殊荣","url":"https://stock-news.laohu8.com/highlight/detail?id=1106467182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106467182?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:08","pubTimestamp":1777460917,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics Corporation）近日宣布，公司董事会成员雷蒙德·德韦克教授（Professor Raymond Dwek, C.B.E., F.R.S.）正式退休。德韦克教授在任期间以其深厚的学术造诣和卓越贡献备受赞誉，其荣休标志着公司治理层一个重要时代的落幕。\n作为曾获授大英帝国司令勋章（C.B.E.）及英国皇家学会院士（F.R.S.）的杰出科学家，德韦克教授在生物医学领域的专业见解为董事会决策提供了重要支撑。他的离任虽令人不舍，但公司对其多年来的服务表示深切感谢，并祝愿他在未来的学术与生活中再创辉煌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","LU1699723380.USD","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180302098","title":"美国联合医疗：Raymond James首予跑赢大市评级，目标价700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180302098","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180302098?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:24","pubTimestamp":1775820297,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）近日获得Raymond James的首次覆盖，该机构给予其\"跑赢大市\"评级，并将目标股价设定为700美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","BK4532","LU1571399168.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159418166","title":"美国联合医疗Miroliverelap®获FDA再生医学先进疗法认定，用于急性肝衰竭治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1159418166","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159418166?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:03","pubTimestamp":1775646225,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其研发的药物Miroliverelap®已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定，适应症为急性肝衰竭。这一认定将加速该疗法的开发和审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1571399168.USD","LU1699723380.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161460841","title":"美国联合医疗股价飙升14.71%：吸入式药物Tyvaso在晚期特发性肺纤维化研究中达成主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1161460841","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161460841?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:32","pubTimestamp":1774877577,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其吸入式药物Tyvaso在一项针对特发性肺纤维化的晚期临床研究中成功达成主要试验目标。受此利好消息提振，该公司股价大幅跃升14.71%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","BK4532","LU1571399168.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109130837","title":"美国联合医疗计划为Tyvaso申请优先审评 补充新药申请将于今夏末提交FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1109130837","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109130837?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:10","pubTimestamp":1774869014,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，将为旗下药物Tyvaso的补充新药申请（sNDA）寻求优先审评资格。该公司计划于今年夏季结束前向美国食品药品监督管理局（FDA）正式提交该项申请。\n优先审评资格将加速FDA对Tyvaso申请的审批流程，若获批准，有望使该药物更早惠及患者。此次申报标志着公司在拓展Tyvaso适应症方面迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","UTHR","LU1571399168.USD","BK4139","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166965135","title":"美国联合医疗宣布Tyvaso®治疗特发性肺纤维化Teton-1关键研究达主要终点，疗效超越Teton-2显著成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1166965135","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166965135?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:03","pubTimestamp":1774868588,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布，其研发的Tyvaso®在治疗特发性肺纤维化的Teton-1关键性研究中成功达到主要临床终点。该研究展现的治疗效果甚至超越了此前Teton-2研究中已令人瞩目的数据，标志着其在IPF治疗领域取得重大突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","BK4532","BK4139","LU1571399168.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177276682","title":"美国联合医疗TETON-2研究达主要终点 Tyvaso治疗52周显著改善患者绝对FVC","url":"https://stock-news.laohu8.com/highlight/detail?id=1177276682","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177276682?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267316,"startTime":"0","endTime":"0","summary":"美国联合医疗宣布，其针对间质性肺病患者开展的TETON-2三期临床研究已达到主要终点。数据显示，治疗52周后，使用Tyvaso吸入溶液的患者在绝对用力肺活量指标上表现出具有统计学意义的显著改善。这项随机双盲安慰剂对照研究，旨在评估Tyvaso在改善ILD患者肺功能方面的疗效与安全性。公司表示将基于该研究结果与全球监管机构进行沟通，推动Tyvaso在更多地区的临床应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4532","BK4139","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188280173","title":"美国联合医疗Tyvaso耐受性良好 安全性特征与既往研究一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1188280173","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188280173?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267315,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布的最新数据显示，其肺动脉高压治疗药物Tyvaso表现出良好的耐受性，药物安全性特征与先前临床试验结果保持一致。\n研究结果显示，Tyvaso在长期使用过程中维持了稳定的安全特性，未出现新的安全性信号。该药物在改善患者运动耐量方面的疗效与已知数据相符，为肺动脉高压患者提供了持续有效的治疗选择。\n此次数据进一步巩固了Tyvaso在肺动脉高压治疗领域的地位，其一致的安全性特征为临床医生和患者提供了更可靠的用药依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","BK4139","LU1699723380.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128744146","title":"美国联合医疗公布Teton-2三期临床试验完整结果 发表于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1128744146","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128744146?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267313,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics）宣布，其Teton-2三期临床试验的完整研究结果已在权威医学期刊《新英格兰医学杂志》上正式发表。该试验的全面数据披露，标志着公司在相关治疗领域的研究取得了重要阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4532","LU1699723380.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618676824","title":"美国联合医疗涨4.57% 股价突破500美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2618676824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618676824?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:30","pubTimestamp":1773063025,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时30分，美国联合医疗股票出现波动，股价大幅上涨4.57%。截至发稿，该股报500.00美元/股，成交量1.0408万股，换手率0.02%，振幅0.94%。美国联合医疗股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Hims & Hers Health, Inc.、美国联合医疗、Medicus Pharma Ltd.涨幅较大，Hims & Hers Health, Inc.、Medicus Pharma Ltd.、Inmed Pharmaceuticals Inc.较为活跃，换手率分别为11.07%、3.17%、2.24%，振幅较大的相关个股有Hims & Hers Health, Inc.、Ironwood医药、Canopy Growth Corporation，振幅分别为2.99%、2.00%、1.87%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213025a6b2aa4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213025a6b2aa4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UTHR","BK4139","BK4532","LU1571399168.USD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159454448","title":"美国联合医疗宣布20亿美元股票回购授权并启动15亿美元加速回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1159454448","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159454448?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:04","pubTimestamp":1773054298,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布了一项高达20亿美元的股票回购授权，并同步启动金额达15亿美元的加速股票回购项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4532","BK4139","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102041348","title":"美国联合医疗尚有5亿美元额度可用于未来一年股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1102041348","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102041348?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054176,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，公司目前仍拥有5亿美元的回购授权额度，该额度将在未来一年内用于实施额外的股份回购计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","LU1571399168.USD","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616558327","title":"美国联合医疗跌2.89% 股价跌破500美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616558327?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:39","pubTimestamp":1772548778,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时39分，美国联合医疗股票出现波动，股价快速跳水2.89%。截至发稿，该股报498.96美元/股，成交量1.582万股，换手率0.04%，振幅2.79%。美国联合医疗股票所在的制药行业中，整体跌幅为0.48%。此外，该公司正在开发一系列项目，其中包括用于治疗肺动脉高压和其他病症的现有产品和新产品的新适应症和输送装置。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223939a69e060f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223939a69e060f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","LU1699723380.USD","UTHR","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116122081","title":"美国联合医疗Ralinepag三期研究达主要终点，临床改善率达47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116122081","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116122081?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:32","pubTimestamp":1772451132,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其肺动脉高压治疗药物Ralinepag的三期临床试验成功达到主要研究终点。数据显示，与安慰剂组相比，Ralinepag治疗组患者实现47%的临床改善率，这一结果标志着该药物在改善患者运动能力和延缓疾病进展方面展现出显著疗效。\n此次突破性进展为肺动脉高压患者提供了新的治疗希望，也进一步巩固了美国联合医疗在罕见病治疗领域的领先地位。研究人员指出，该药物独特的作用机制可能为现有治疗方案提供重要补充。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","UTHR","LU1571399168.USD","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112670692","title":"美国联合医疗公布ralinepag关键性肺动脉高压研究结果：临床恶化风险降低55%，疗效卓越且具高度统计学意义","url":"https://stock-news.laohu8.com/highlight/detail?id=1112670692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112670692?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:30","pubTimestamp":1772451029,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其在研药物ralinepag于关键性肺动脉高压研究中取得突破性成果——临床恶化风险显著降低55%。该结果展现出卓越的疗效，并具有高度统计学意义。\n这项研究针对肺动脉高压患者群体展开，数据显示ralinepag治疗组在主要终点指标上表现突出。风险降低幅度远超常规预期，统计显著性达到较高水平，为药物后续审批及临床应用奠定坚实基础。\n肺动脉高压作为进行性重症疾病，临床恶化风险直接影响患者预后。此次研究成果不仅验证了ralinepag的治疗潜力，更为该疾病领域提供了新的治疗方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","UTHR","LU1699723380.USD","BK4139","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616784726","title":"美国联合医疗2025财年实现净利润13.35亿美元，同比增加11.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784726","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784726?lang=zh_cn&edition=full","pubTime":"2026-03-01 00:00","pubTimestamp":1772294453,"startTime":"0","endTime":"0","summary":"3月1日，美国联合医疗公布财报，公告显示公司2025财年净利润为13.35亿美元，同比增加11.72%；其中营业收入为31.83亿美元，同比增加10.64%，每股基本收益为30.13美元。从资产负债表来看，美国联合医疗总负债8.73亿美元，其中短期债务0.00美元，资产负债比为9.13，流动比率为6.61。机构评级：截至2026年3月1日，当前有11家机构对美国联合医疗目标价做出预测，其中目标均价为574.00美元，其中最低目标价为466.00美元，最高目标价为655.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000113a43b9698&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000113a43b9698&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1122184195","title":"财报前瞻 ｜美国联合医疗本季度营收预计同比增0.11，机构观点看空占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1122184195","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122184195?lang=zh_cn&edition=full","pubTime":"2026-02-18 10:40","pubTimestamp":1771382422,"startTime":"0","endTime":"0","summary":"美国联合医疗将于2026年02月25日盘前发布最新季度财报，市场聚焦收入增速、利润结构与合规风险的变动。市场一致预期本季度营收为8.17亿USD，同比0.11；调整后每股收益为6.87，同比0.09；EBIT为4.02亿USD，同比0.09，当前未见公司层面对毛利率与净利率的明确预测披露。上季度公司营收为7.99亿USD，同比0.07；毛利率为87.38；归属母公司的净利润为3.39亿USD；净利率为42.36；调整后每股收益为7.16，同比0.12。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻 ｜美国联合医疗本季度营收预计同比增0.11，机构观点看空占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196123529","title":"美国联合医疗公布Miroliverelap®治疗急性肝衰竭一期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1196123529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196123529?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:02","pubTimestamp":1769428924,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）近日披露了其创新药物Miroliverelap®针对急性肝衰竭患者的一期临床试验数据，结果显示疗效积极。该研究评估了药物的安全性与耐受性，初步数据表明患者肝功能指标呈现改善趋势，未出现严重不良反应。这一突破为后续临床研究奠定了基础，有望为急性肝衰竭治疗提供新方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","BK4139","LU1699723380.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516854800","title":"美国联合医疗2024财年实现净利润11.95亿美元，同比增加21.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516854800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516854800?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931230,"startTime":"0","endTime":"0","summary":"3月3日，美国联合医疗公布财报，公告显示公司2024财年净利润为11.95亿美元，同比增加21.32%；其中营业收入为28.77亿美元，同比增加23.58%，每股基本收益为26.44美元。从资产负债表来看，美国联合医疗总负债9.94亿美元，其中短期债务3.00亿美元，资产负债比为7.49，流动比率为5.25。机构评级：截至2025年3月3日，当前有10家机构对美国联合医疗目标价做出预测，其中目标均价为407.90美元，其中最低目标价为293.00美元，最高目标价为600.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000045abe4ac8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000045abe4ac8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unither.com","stockEarnings":[{"period":"1week","weight":-0.0162},{"period":"1month","weight":-0.0533},{"period":"3month","weight":0.0235},{"period":"6month","weight":0.0376},{"period":"1year","weight":0.8394},{"period":"ytd","weight":0.1013}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"United Therapeutics Corporation于1996年6月成立于特拉华。它是一家生物科技公司，致力于能解决患有慢性病和有生命危险病人未被满足的医疗需求的独特产品的开发和商业化。它的收入主要来源于曲前列尼尔、Tyvaso和他达拉非的销售。他们的市场和销售人员会努力使他们的产品在他们那些被授权的国家买到。这些主要是由他们在美国的专业经销商和其它的国际经销商做的。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.005391},{"month":2,"riseRate":0.518519,"avgChangeRate":0.021742},{"month":3,"riseRate":0.481481,"avgChangeRate":0.013636},{"month":4,"riseRate":0.407407,"avgChangeRate":-0.022031},{"month":5,"riseRate":0.555556,"avgChangeRate":0.047064},{"month":6,"riseRate":0.518519,"avgChangeRate":0.026478},{"month":7,"riseRate":0.592593,"avgChangeRate":0.043947},{"month":8,"riseRate":0.518519,"avgChangeRate":0.052081},{"month":9,"riseRate":0.444444,"avgChangeRate":0.055311},{"month":10,"riseRate":0.62963,"avgChangeRate":-0.003162},{"month":11,"riseRate":0.62963,"avgChangeRate":0.05551},{"month":12,"riseRate":0.592593,"avgChangeRate":0.029941}],"exchange":"NASDAQ","name":"美国联合医疗","nameEN":"United Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国联合医疗,UTHR,美国联合医疗股票,美国联合医疗股票老虎,美国联合医疗股票老虎国际,美国联合医疗行情,美国联合医疗股票行情,美国联合医疗股价,美国联合医疗股市,美国联合医疗股票价格,美国联合医疗股票交易,美国联合医疗股票购买,美国联合医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}